<DOC>
	<DOC>NCT01196546</DOC>
	<brief_summary>This study will assess the efficacy and safety of combination therapy of vildagliptin/metformin in patients with T2DM inadequately controlled with metformin 1,000 mg/day.</brief_summary>
	<brief_title>Efficacy and Safety of Combination Therapy of Vildagliptin/Metformin in Patients in Type 2 Diabetes Mellitus (T2DM)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 Diabetes mellitus patients who are treated with metformin monotherapy 1,000 mg daily for at least 3 months The patient is required to have HbA1c 6.511.0% BMI in the range of 2248 kg/m2 Severe or uncontrolled Type 2 diabetes mellitus (HbA1c&gt; 11.0%) Acute metabolic diabetes complications such as ketoacidosis or hyperosmolar state (coma) within the past 6 months Congestive heart failure requiring pharmacologic treatment Any of following within past 6 months: (1) myocardial infarction; (2) unstable angina (3) coronary artery bypass surgery or percutaneous coronary intervention Liver disease such as cirrhosis or chronic active hepatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>vildagliptin</keyword>
	<keyword>metformin</keyword>
</DOC>